For research use only. Not for therapeutic Use.
JNJ-7706621（Cat No.:I003572）is a potent, dual inhibitor of cyclin-dependent kinases (CDKs) and aurora kinases, key regulators of the cell cycle and mitosis. By inhibiting these enzymes, JNJ-7706621 disrupts cell cycle progression, leading to cell growth arrest and apoptosis, particularly in rapidly dividing cancer cells. It has shown efficacy in preclinical cancer models, making it valuable for cancer research. JNJ-7706621 is widely used to study the mechanisms of cell cycle control and to explore novel therapeutic strategies targeting CDKs and aurora kinases for cancer treatment.
| Catalog Number | I003572 |
| CAS Number | 443797-96-4 |
| Synonyms | 4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide |
| Molecular Formula | C₁₅H₁₂F₂N₆O₃S |
| Purity | ≥95% |
| Target | Aurora Kinase |
| Solubility | DMSO ≥75mg/mL Water <1.2mg/mL Ethanol ≥2.8mg/mL |
| Storage | 3 years -20C powder |
| IC50 | 9 nM(CDK1/Cyclin B); 4 nM(CDK2/Cyclin A); 3 nM(CDK2/Cyclin E); 11 nM (Aurora-A) |
| IUPAC Name | 4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide |
| InChI | InChI=1S/C15H12F2N6O3S/c16-10-2-1-3-11(17)12(10)13(24)23-14(18)21-15(22-23)20-8-4-6-9(7-5-8)27(19,25)26/h1-7H,(H2,19,25,26)(H3,18,20,21,22) |
| InChIKey | KDKUVYLMPJIGKA-UHFFFAOYSA-N |
| SMILES | C1=CC(=C(C(=C1)F)C(=O)N2C(=NC(=N2)NC3=CC=C(C=C3)S(=O)(=O)N)N)F |
| Reference | </br>1:Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases. Matsuhashi A, Ohno T, Kimura M, Hara A, Saio M, Nagano A, Kawai G, Saitou M, Takigami I, Yamada K, Okano Y, Shimizu K.Curr Cancer Drug Targets. 2012 Jul;12(6):625-39. PMID: 22463590 </br>2:Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621. Danhier F, Ucakar B, Magotteaux N, Brewster ME, Préat V.Int J Pharm. 2010 Jun 15;392(1-2):20-8. doi: 10.1016/j.ijpharm.2010.03.018. Epub 2010 Mar 11. PMID: 20226846 </br>3:Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621. Huang S, Connolly PJ, Lin R, Emanuel S, Middleton SA.Bioorg Med Chem Lett. 2006 Jul 15;16(14):3639-41. Epub 2006 May 6. PMID: 16682186 </br>4:The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Emanuel S, Rugg CA, Gruninger RH, Lin R, Fuentes-Pesquera A, Connolly PJ, Wetter SK, Hollister B, Kruger WW, Napier C, Jolliffe L, Middleton SA.Cancer Res. 2005 Oct 1;65(19):9038-46. PMID: 16204078 Free Article |
